A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)

被引：0
|
作者：
Anders, Carey [1 ]
Le Rhun, Emily [2 ]
Bachelot, Thomas [3 ]
Yardley, Denise [4 ]
Awade, Ahmad [5 ]
Conte, Pierre Franco [6 ]
Cabos, Peter [7 ]
Bear, Melissa [8 ]
Tolaney, Sarah [9 ]
机构：
[1] Duke Canc Inst, Durham, NC USA
[2] Univ Hosp, Lille, France
[3] Ctr Leon Berard, Lyon, France
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Inst Jules Bordet, Brussels, Belgium
[6] Univ Padua, Padua, Italy
[7] Univ Denver, Denver, CO USA
[8] Elli Lilly, Indianapolis, IN USA
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [21] Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2-metastatic breast cancer
    Fitzgerald, D. M.
    Henderson, L. E.
    Isakoff, S. J.
    Moy, B.
    Oh, K.
    Shih, H. A.
    Dias-Santagata, D.
    Borger, D. R.
    Iafrate, A. J.
    Brastianos, P. K.
    Bardia, A.
    Juric, D.
    CANCER RESEARCH, 2017, 77
  • [22] Real-world clinical outcomes in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
    Tolaney, Sara M.
    Punie, Kevin
    Kurian, Allison W.
    Ntalla, Ioanna
    Verret, Wendy
    Sadetsky, Natalia
    Sjekloca, Nikoleta
    Stokes, Michael
    Jhaveri, Komal L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Experience with eribulin in HR+/HER2-metastatic breast cancer, including a male
    Munoz Sanchez, Maria del Mar
    Soriano Rodriguez, Maria del Carmen
    Molina Garrido, Maria Jose
    Lopez-Gonzalez, Ana
    Garcia-Palomo, Andres
    Lopez-Gonzalez, Laura
    Plata Fernandez, Maria Yessica
    Luque Caro, Natalia
    Sanchez Rovira, Pedro
    FUTURE ONCOLOGY, 2018, 14 (07) : 5 - 12
  • [24] Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?
    Loibl, Sibylle
    Holtschmidt, Johannes
    LANCET, 2023, 402 (10411): : 1394 - 1395
  • [25] Physician survey in the treatment of HR+/HER2-metastatic breast cancer in Egypt
    Aboelkheir, E.
    Ashour, A.
    Fadel, S.
    Arafat, W.
    BREAST, 2021, 56 : S31 - S31
  • [26] Real-world outcomes in patients with brain metastases secondary to HR+/HER2- MBC treated with abemaciclib and local intracranial therapy
    Gathirua-Mwangi, Wambui
    Martin, Holly
    He, Dan
    Zheng, Shen
    Sheffield, Kristin M.
    John, Jincy
    Yamazawa, Erika
    Rybowski, Sarah
    Brastianos, Priscilla K.
    ONCOLOGIST, 2024,
  • [27] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    CANCER RESEARCH, 2016, 76
  • [28] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [29] Abemaciclib for the treatment of HR+/HER2- breast cancer
    Exman, Pedro
    Tolaney, Sara M.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
  • [30] Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR) HER2-metastatic breast cancer (MBC)
    Tolaney, S. M.
    Cortes, J.
    Dickler, M. N.
    Zamora, E.
    Caldwell, C. W.
    Nguyen, T. S.
    Nanda, S.
    Koustenis, A.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2016, 27
12345